Climb Bio (CLYM) Non Operating Investment Income (2021 - 2026)
Climb Bio's (CLYM) quarterly Non Operating Investment Income came in at -$278000.0 in Q1 2026, down 205.7% YoY from $263000.0 in Q1 2025, and down 717.65% on a QoQ basis from -$34000.0 in Q4 2025.
Powered by 
Analysis
Climb Bio (CLYM) Non Operating Investment Income (2021 - 2026) Analysis & Trends
Climb Bio (CLYM) has 6 years of Non Operating Investment Income data on file, last reported at -$278000.0 in Q1 2026.
- Quarterly Non Operating Investment Income fell 205.7% year-over-year to -$278000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$129000.0 (down 145.1% YoY) and the FY2025 annual result came in at $412000.0, up 1548.0% from the prior year.
- Non Operating Investment Income retreated to -$278000.0 in Q1 2026, from -$34000.0 in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $263000.0 in Q1 2023 to a low of -$398000.0 in Q1 2022.
- A 5-year average of $17500.0 and a median of $23500.0 in 2022 frame the typical range for Non Operating Investment Income.
- Annual changes were most pronounced in 2024 — Non Operating Investment Income slumped 2077.78% — and 2025, when it surged 13050.0%.
- Tracing CLYM's Non Operating Investment Income over 5 years: stood at $223000.0 in 2022, then plunged by 95.96% to $9000.0 in 2023, then tumbled by 2077.78% to -$178000.0 in 2024, then jumped by 80.9% to -$34000.0 in 2025, then sank by 717.65% to -$278000.0 in 2026.
- The last three Non Operating Investment Income figures came in at -$278000.0 (Q1 2026), -$34000.0 (Q4 2025), and $151000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | Climb Bio | 1.20 Bn | 1.20 Bn | - | -224,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -224,000.00 |
| Mar 31, 2026 | -278,000.00 |
| Dec 31, 2025 | -34,000.00 |
| Sep 30, 2025 | 151,000.00 |
| Jun 30, 2025 | 32,000.00 |
| Mar 31, 2025 | 263,000.00 |
| Dec 31, 2024 | -178,000.00 |
| Sep 30, 2024 | 201,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Dec 31, 2023 | 9,000.00 |
| Sep 30, 2023 | 24,000.00 |
| Jun 30, 2023 | 60,000.00 |
| Mar 31, 2023 | 263,000.00 |
| Dec 31, 2022 | 223,000.00 |
| Sep 30, 2022 | 23,000.00 |
| Jun 30, 2022 | -83,000.00 |
| Mar 31, 2022 | -398,000.00 |
| Dec 31, 2021 | -105,000.00 |
| Sep 30, 2021 | 18,000.00 |